Building on TNFAIP3’s mechanistic duality as a ubiquitin-editing hub for NF-κB (COPD pathogenesis) and circadian rhythm modulation (insomnia pathophysiology), its therapeutic exploitation warrants multi-modal drug engineering. The gene discussed is NFKB1; the disease is insomnia measurement.